Laurus Labs Limited (NSE:LAURUSLABS)

Market Cap	552.54B +80.9%
Revenue (ttm)	67.22B +27.5%
Net Income	8.43B +321.1%
EPS	15.61 +321.7%
Shares Out	539.86M
PE Ratio	65.57
Forward PE	57.05
Dividend	1.60 (0.16%)
Ex-Dividend Date	Oct 31, 2025

Volume	6,517,137
Average Volume	1,706,659
Open	1,019.00
Previous Close	1,023.50
Day's Range	1,000.50 - 1,021.00
52-Week Range	517.65 - 1,141.00
Beta	0.28
RSI	52.70
Earnings Date	Apr 24, 2026

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 6,167
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: LAURUSLABS

Financial Performance

In fiscal year 2025, Laurus Labs's revenue was 55.54 billion, an increase of 10.18% compared to the previous year's 50.41 billion. Earnings were 3.58 billion, an increase of 123.18%.